Skip to content
Funding & Investment

MegaRobo Funding: Chinese AI-for-Science Firm Raises Nearly $200 Million

MegaRobo’s automated laboratory technology combining robotics and artificial intelligence for scientific research.

China-based technology company MegaRobo has raised nearly $200 million in a new funding round, bringing fresh investment into the growing market for artificial intelligence-powered scientific research and laboratory automation.

The round includes participation from the Oman Investment Authority (OIA), the sovereign wealth fund of Oman, and CMB International. Existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures also backed the financing, according to the company’s announcement on November 19.

MegaRobo said the capital will support further investment in its core technology, international expansion of its AI for Science business and the development of infrastructure that connects artificial intelligence with complex physical environments.

MegaRobo funding brings new international investors

The latest financing adds a sovereign wealth fund to MegaRobo’s investor group. CMB International also participated as a new investor, while several existing backers continued their support.

The company said it has raised approximately $600 million across multiple funding rounds. That total includes an earlier Series C financing of nearly $300 million, co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia. Pavilion Capital, part of Temasek’s Seviora Group, also participated in that round.

MegaRobo has not disclosed the exact amount contributed by each investor in the latest financing. It has also not announced a valuation or identified the new round by a specific series name.

How MegaRobo applies AI to scientific research

Founded in Beijing in 2016, MegaRobo operates in the AI for Science (AI4S) sector. Its work combines artificial intelligence, robotics, software and automated laboratory equipment to support research and pharmaceutical development.

The company uses technologies including machine learning, deep learning and AI agents to process scientific data, identify patterns and support research workflows. Its systems are designed to connect computational analysis with experiments conducted using physical laboratory equipment.

This approach could help researchers move more quickly between developing a hypothesis, designing an experiment and analysing its results. Automating parts of that process may also reduce repetitive manual work and make laboratory operations more consistent.

However, AI-assisted research does not remove the need for scientific validation. Experimental results still require scrutiny, and researchers must assess whether findings are reliable and reproducible.

Why investment in AI-powered laboratories is growing

The MegaRobo funding round reflects investor interest in AI systems that can operate beyond digital applications. In scientific research, the combination of software, robotics and laboratory equipment offers a way to connect AI-generated analysis with physical experiments.

Pharmaceutical research is one potential area of impact. Drug development involves extensive testing, data analysis and repeated experiments. Automated systems could help laboratories handle some of these tasks more efficiently, although they cannot guarantee shorter development timelines or successful treatments.

MegaRobo plans to use the new capital to expand its AI-for-science operations globally and strengthen the technology behind its systems. The company's ability to turn that investment into wider adoption will depend on the performance of its products, research partnerships and commercial execution.

The latest raise also shows how funding for AI is extending into specialised infrastructure. Rather than focusing only on models and software, investors are backing companies attempting to connect AI with the equipment and workflows used in real-world industries.